Search clinical trials for: PD-1 antibody (SHR-1210)

Total 1490 results

Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Theravance Biopharma

Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Constipation

United States
Fudan University

Recruiting

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） (TORCH-E)

Early Low Rectal Cancer

China
Fudan University

Recruiting

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer (TORCH)

Locally Advanced Rectal Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

Oral Cancer | PD-1

China
Hangzhou Cancer Hospital
Anhui Kedgene Biotechnology Co.,Ltd

Completed

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Esophageal Cancer

China
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
ThromboGenics

Completed

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States
ThromboGenics

Completed

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Limited-metastatic G/GEJ Adenocarcinoma (ROSETTE)

Gastric Cancer | GastroEsophageal Cancer

China
Sinocelltech Ltd.

Terminated

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Squamous-cell Non-Small-cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Terminated

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (NEOPCOSCC)

Oral Squamous Cell Carcinoma

China
AVAVA, Inc.

Completed

AVAVA SR-1 Wrinkles and BPL Study

Wrinkle | Benign Pigmented Lesion

United States
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital; Henan Provincial People's Hospital; The First People's Hospital...

Unknown

A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

Solid Tumor
Shanghai Celfuture Biotech Co., Ltd.

Not yet recruiting

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Colorectal Cancer

China
Beijing Friendship Hospital

Recruiting

Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

Colorectal Neoplasms

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Liang Peng
Guangzhou Virotech Pharmaceutical Co., Ltd.

Unknown

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Advanced/Metastatic Hepatocellular Carcinoma
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
The Affiliated Hospital of Xuzhou Medical University

Not yet recruiting

Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor

Advanced Solid Tumor

China
Shandong Cancer Hospital and Institute
BeiGene

Active, not recruiting

A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (Notable-HCC)

Hepatocellular Carcinoma

China
Agenus Inc.

Withdrawn

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Angiosarcoma
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital; The First People's Hospital of Yunnan Province/First People... and other collaborators

Unknown

A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors (DC-CIK)

Solid Tumor
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Shen Lin
NeoCura

Not yet recruiting

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

Gastric Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Fudan University

Withdrawn

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Intrahepatic Cholangiocarcinoma

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Sun Yat-sen University

Active, not recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
Eye & ENT Hospital of Fudan University

Active, not recruiting

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Chemotherapy | Immunotherapy | Hypopharyngeal Carcinoma

China
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Chinese PLA General Hospital

Recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

China
Novita Pharmaceuticals, Inc.

Recruiting

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Hospices Civils de Lyon

Completed

Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

Hodgkin Lymphoma

France
Chen Xiaoping

Completed

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Recurrence | HCC

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC (RAIC)

Rectal Neoplasms

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction (TRACE)

Esophageal Cancer

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody

Search clinical trials for: PD-1 antibody (SHR-1210)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations